JS105 + toripalimab

JS105 + toripalimab is a **combination regimen** consisting of JS105, an experimental anti-tumor agent, and toripalimab, a selective, recombinant, humanized monoclonal antibody against programmed death protein 1 (PD-1). Toripalimab inhibits the interaction between PD-1 and its ligands, thereby restoring T-cell-mediated immune responses against tumor cells. Toripalimab has demonstrated efficacy in the treatment of several cancers, particularly nasopharyngeal carcinoma, both as monotherapy and in combination with chemotherapy[1][2][3][5]. JS105 is being evaluated in ongoing clinical studies in combination with anti-tumor therapies in patients with solid tumors[5]. The detailed mechanism of JS105 has not been disclosed in the available clinical trial registries.

Brand names

Tuoyi

Other names

JS105JS-105JS 105toripalimabTuoyi